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Abstract
Background: In the last years, the transmembrane proteoglycan NG2 has gained interest as a therapeutic target
for the treatment of diverse tumor types, including gliomas, because increases of its expression correlate with
dismal prognosis. NG2 has been shown to function as a co-receptor for PDGF ligands whose aberrant expression is
common in gliomas. We have recently generated a glioma model based on the overexpression of PDGF-B in
neural progenitors and here we investigated the possible relevance of NG2 during PDGF-driven gliomagenesis.
Methods: The survival curves of NG2-KO mice overexpressing PDGF-B were compared to controls by using a Log-
rank test. The characteristics of tumors induced in NG2-KO were compared to those of tumors induced in wild
type mice by immunostaining for different cell lineage markers and by transplantation assays in adult mice.
Results: We showed that the lack of NG2 does not appreciably affect any of the characterized steps of PDGF-
driven brain tumorigenesis, such as oligodendrocyte progenitor cells (OPC) induction, the recruitment of bystander
OPCs and the progression to full malignancy, which take place as in wild type animals.
Conclusions: Our analysis, using both NG2-KO mice and a miRNA based silencing approach, clearly demonstrates
that NG2 is not required for PDGF-B to efficiently induce and maintain gliomas from neural progenitors. On the
basis of the data obtained, we therefore suggest that the role of NG2 as a target molecule for glioma treatment
should be carefully reconsidered.
Background
Gliomas are tumors of the central nervous system often
characterized by poor survival. Their most aggressive
form, glioblastoma, exhibits a dismal prognosis mainly
due to its prominent infiltrative ability and to its high
radio- and chemo-resistance. Because of this, it is of pri-
mary importance to identify molecules that can be used
as therapeutic targets. The transmembrane chondroitin
sulfate proteoglycan NG2 has been proposed as one of
these candidates [1,2].
NG2 is expressed in human gliomas and its expression
correlates to their malignancy [3-6] and chemo-resis-
tance [7]. A major role for NG2 in glioma progression
could reside in its ability to promote neoangiogenesis
[ 4 , 8 , 9 ]a n ds o m er e p o r t ss h o w e dt h a ti tc o u l da l s o
be involved in other critical processes such as cell
migration and cell proliferation [10]. Many of these
effects are due to the ability of NG2 to influence extra-
cellular signaling by interacting with integrins [10-12]
and growth factor receptors [13-15]. In particular, NG2
was reported to physically interact with PDGF receptor-
alpha and its ligand PDGF-A, leading to enhanced
PDGF-A signaling activity [13-16]. Importantly, PDGF
signaling is commonly altered in human high grade glio-
mas, which often overexpress PDGF-A or -B ligands or
their receptors [17-21]. Furthermore, many studies per-
formed in mouse clearly demonstrate that sustained
PDGF-A or -B signaling induces gliomas that closely
resemble the human neoplasia [22-30] and are charac-
terized by high NG2 expression levels [24,25,31].
Moreover, we recently demonstrated that PDGF-B over-
expression is able to induce NG2 expression in neural
precursors [23]. The above data suggest a potential role
for the proteoglycan NG2 in gliomagenesis. Notably,
even if adult NG2-KO mice do not show any strong
phenotype [13,32], it has been reported, though on the
basis of a limited sample, that the lack of NG2 could be
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induced tumors [33] indicating the possibility to disrupt
NG2 activity as a way to treat gliomas.
Here, in order to investigate the potential role of this
proteoglycan in the formation and progression of
PDGF-expressing gliomas, we tested the ability of
PDGF-B overexpression to induce brain tumors in
NG2-KO mice. The generation of high grade gliomas in
this context clearly demonstrated that NG2 is not neces-
sary for the induction and progression of glial tumors,
reducing the chances of treating gliomas by inhibiting
the function of NG2.
Methods
Retroviral vectors
The cDNA of human PDGF-B, derived from the RCAS-
pBIG plasmid (kindly provided by Dr. E. Holland, Mem-
orial Sloan-Kettering Cancer Center, New York, USA),
was inserted into the SalI site upstream the IRES
sequence of the pCEG retroviral backbone (kindly pro-
vided by Gordon Fishell, The Skirball Institute of Bio-
molecular Medicine, New York, USA), generating the
PDGF-B/GFP construct. The same PDGF-B cDNA was
inserted also into the blunted PmeI/SfiI sites of the
pCAG:Ds-Red vector (kindly provided by Dr. M. Goetz,
Institute of Stem Cell Research, Germany), upstream the
IRES-Ds-Red reporter cassette to form the PDGF-B/Ds
Red vector. The engineered miRNA directed against the
mRNA of NG2 (the sequence is available on request)
was designed using the BLOCK-iT RNAi Designer soft-
ware of Invitrogen and cloned following the BLOCK-iT™
Pol II miR RNAi Expression Vector kit (Invitrogen) into
the gateway cassette (Invitrogen) of the pCDB-GW vec-
tor together with the EmGFP cDNA. As negative con-
trol we used the miRneg oligo supplied in the kit and
we cloned it in the pCDB-GW plasmid. The pCDB-GW
vector was derived by the pCEG vector after the dele-
tion of the GFP cDNA and the insertion of the gateway
cassette in the SalI site.
Replication-defective retroviral supernatants were pre-
pared by transiently transfecting plasmids into Phoenix
packaging cells as described in [34].
Cell cultures
Primary cultures of embryonic neural precursors were
obtained from embryonic day 14 (E14) mouse embryos.
Dorsal and ventral regions were separated and kept in
HBSS buffer (Invitrogen, Carlsbad, CA) added with 1
mM HEPES (Invitrogen). Forebrain explants were then
incubated in 1 ml of trypsin/EDTA (Invitrogen) at 37°C
for 15 minutes and then mechanically dissociated with a
glass pipette in DMEM medium added with 10% foetal
calf serum (Invitrogen). Cells were then plated at a den-
sity of 3.5 × 10
5 cells/cm
2 onto poly-D-lysine (Sigma, St.
Louis, MO) coated coverslips. Retroviral supernatants
were added immediately after plating. Cells were cul-
t u r e di nac h e m i c a l l yd e f i n e dm e d i u m( S A T Om e d i u m
[35]) and fixed in 4% paraformaldehyde after 6 days.
Tumor cell cultures were established as described in
[25]. Briefly, tumor masses were dissected under fluores-
cence microscope by taking advantage of the expression
of GFP and trypsinized for 20 minutes. After trypsin
neutralization with serum-containing DMEM medium,
cells were resuspended in DMEM-F12 added with B27
supplement, human bFGF (20 ng/ml, Invitrogen) and
EGF (20 ng/ml, Invitrogen) and plated on Matrigel-
coated flasks (BD Biosciences, San Jose, CA). For the
miR-NG2 experiments, tumor cell cultures derived from
PDGFB/DsRed induced gliomas were transduced by
adding high titre retroviral supernatants one day after
cell splitting. Before in vivo injections the percentage of
GFP-positive cells was determined counting the cells
using a burker chamber under a fluorescent microscope.
Quantification of cell foci density
For foci formation, cells were allowed to overgrow on 6-
well plates and then the average number of foci in 4
mm
2 area was determined for two wild type and two
NG2-KO glioma cultures. For each well, three random
areas were analyzed and the count was repeated for
three days to monitor foci formation during time. The
experiment was then repeated twice.
Quantification of infiltrating cells
For infiltrating cell quantification at least two NG2-KO
and three wild type gliomas were analyzed. Tumor cells
migrated in the healthy brain tissue were identified in
brain sections by means of their immunopositivity to
GFP. To determine the number of infiltrated cells, brain
regions of 0.1 mm
2 near the tumor masses were ana-
lyzed. The number of infiltrating cells per mm
2 was
then obtained for each section and used to calculate the
average number of infiltrating cells for the two tumor
groups (wild type and NG2-KO).
In vivo injections
Mice were handled in agreement with Italian guidelines
and regulations about animal use for scientific purposes
(D.lvo 27/01/1992, n. 116). All procedures were approved
by the Ethical Committee for Animal Experimentation of
the National Institute of Cancer Research and by the Ita-
lian Ministry of Health. All experiments were performed
on C57BL/6 mice and C57BL/6 NG2 null mice (kindly
provided by Dr. William B. Stallcup) which in the
text are referred to as wild type and NG2-KO mice,
respectively.
In utero intraventricular injections were performed on
anesthetized pregnant dams at the fourteenth day of
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exposed and embryos were injected within the telence-
phalic ventricles with approximately 2 μlo fr e t r o v i r a l
suspension containing 1% polybrene (Sigma) to facilitate
cell infection. After birth, injected animals were daily
monitored and sacrificed at the appearance of neurolo-
gic symptoms. Brains were photographed under the
fluorescence microscope, fixed over-night in 4% parafor-
maldehyde, cryoprotected in 20% sucrose, frozen and
sectioned with a cryostat.
Cells transplantation into adult mouse brains were
performed as previously described in [25] with the help
of a stereotaxic table using the following coordinates
from the Bregma: AP, 1.0 mm; L, 1.5 mm left and 2.5
mm below the skull surface. Animals were injected with
15000-100000 GFP-positive cells and then monitored
daily for the appearance of neurological symptoms.
Immunostaining
Immumostainings on brain sections or cultured cells
were performed using the following antibodies: mouse
monoclonal antibodies against Nestin (1:250; BD Phar-
mingen, San Diego, CA) and glial fibrillary acidic protein
(GFAP, 1:200; Sigma); rabbit polyclonal antibodies
against Olig2 (1:200; Sigma) and NG2 (1:300; Chemicon-
Millipore, Billerica, MA); chicken polyclonal antisera
against GFP (1:500; Abcam, Cambridge, United King-
dom); rat monoclonal antibody against PDGFR-alpha
(1:100; BD Pharmingen) and CD31 (1:500; BD Pharmin-
gen). Binding of primary antibodies was revealed with
appropriate secondary Alexa Fluor 488 (1:500; Invitro-
gen), Dy-Light 488 or Dy-Light 549 (1:500; Jackson
Immunoresearch, West Grove, PA) or Cy3 (1:100; Jack-
son Immunoresearch)-conjugated antibodies. Nuclei
were stained with 4’,6-diamidino-2-phenylindole (DAPI)
solution (1 μg/ml; Sigma). Fluorescence images were ana-
lyzed with the ImageJ softwar e( W . S .R a s b a n d ,I m a g e J ,
US National Institutes of Health, Bethesda, MD; http://
rsb.info.nih.gov/ij/, 1997-2007).
Vessel density quantification
Blood vessels were identified by immunopositivity to the
CD31 antigen. CD31-stained sections from three wild
type and two NG2-KO PDGF-B induced gliomas were
analyzed. For each glioma, two different sections were
taken, including at least two microphotographs for each
section. In each microphotograph, at least two regions
of 0.06 mm
2 within the tumor were randomly selected
to measure the area occupied by CD31 positive cells.
This was done by using a threshold mask in the ImageJ
software to circumscribe the immunopositive regions
whose areas were measured by using the wand tool.
Hence, for each section the percentage of CD31 positive
area in the tumor were calculated as the ratio between
the sum of CD31-positive areas and the sum of the
areas of the analyzed regions. At this point, the average
of the percentage of CD31 positive areas was calculated
for each tumor and for the two tumor groups (wild type
and NG2-KO).
Quantitative PCR
RNA was extracted from two wild type and two NG2-
KO PDGF-B induced glioma cultures with QIAzol
reagent (Qiagen s.p.a., Milan, Italy) according to the
manufacturer’s guidelines. cDNA was then obtained
from 500 ng of RNA using the iScript retrotranscription
kit (Bio-Rad Laboratories, Her c u l e s ,C A ) .Q u a n t i t a t i v e
real-time polymerase chain reaction (PCR) was per-
formed on 1:100 of the retrotranscription reaction using
iQ SYBRGreen Supermix (Bio-Rad Laboratories). PCR
was performed in triplicate and repeated twice. PDGF-B
mRNA quantifications were normalized to the house-
keeping gene Rpl41 (NM_018860). The sequences of the
primers are available on request.
Western blot
T w oN G 2 - K Oa n dt w ow i l dt y p eP D G F - Bi n d u c e d
glioma cultures were harvested in lysis buffer containing:
50 mM HEPES (pH 7.5), 5 mM EDTA, 150 mM NaCl,
1% Triton® X-100 detergent and protease inhibitors
(Complete, Roche Applied Science). The level of PDGFR-
alpha and phosphorylated PDGFR-alpha were previously
normalized to alpha-tubulin, then the ratio between the
activated and the total receptor was considered. Western
blot was performed using the following antibodies:
mouse anti-phospho PDGFR-alpha (1:1000; Gentaur
Molecular Products, Bruxelles, Belgium), mouse anti-
alpha-tubulin (1:5000, Sigma), rat anti-PDGFR-alpha
(1:5000, BD Pharmingen), and the secondary anti-mouse
(1:5000, Pierce) and anti-rat (1:5000, GE Healthcare)
antibodies conjugated to HRP.
Data analysis
Means and standard errors were calculated from differ-
ent experiments. “n”; denotes the number of cells
counted in the in vitro experiments or the number of
animals used for in vivo experiments. “nExp” denotes
the number of independent experiments performed. The
threshold for statistical significance, which was deter-
mined with a 2-tailed Student’s t-test, was considered as
P < 0.05.
Results
We previously demonstrated that an early event follow-
ing the retroviral overexpression of PDGF-B consists of
the re-specification of cultured embryonic neural pre-
cursor cells to an oligodendroglial identity [23]. Based
on the roles of NG2 in modulating PDGF signaling in
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is required for PDGF-B to influence the fate of neural
progenitor cells. We cultured E14 progenitor cells from
the cerebral cortex of both NG2-KO and wild type mice
and we infected them with high titre replication-defi-
cient retroviruses coding for PDGF-B and the GFP
fluorescent reporter (PDGF-B/GFP). Six days after infec-
tion, the cultures were immunostained for Olig2 to
quantify the percentage of differentiating OPCs. The
analysis showed that both wild-type and NG2-KO cul-
tures responded in the same way to PDGF-B transduc-
tion. PDGF-B was able to significantly increase the
percentage of Olig2-positive cells compared to cultures
transduced with a control vector carrying only the
reporter gene (Figure 1A). In particular, in the wild
type, Olig2-positive cells raised from 30 ± 4% (n =
3500) to 50 ± 2% (n = 5300, nExp = 2, ttest p ≤ 0.05)
and, in the NG2-KO cultures, from 27 ± 2% (n = 3900)
to 45 ± 1% (n = 5100, nExp = 3, ttest p ≤ 0.01). Similar
results were obtained with cultures derived from the
ganglionic eminences (GE; Figure 1B).
The above data demonstrate that NG2 is not neces-
sary for PDGF-B overexpression to induce an oligoden-
droglial fate in cultured neural progenitor cells.
Recently it has been proposed that NG2 may have a
role in the induction of gliomas by PDGF-B [33], despite
the fact that NG2 has been previously shown to specifi-
cally influence only PDGF-A signaling [13-16]. We
therefore decided to clarify this issue by testing whether
NG2 may affect PDGF-B-induced gliomagenesis in a
model that we recently established, which is based on in
vivo transduction of embryonic mouse neural progeni-
tors [23,25]. Telencephalic progenitors of NG2-KO
mouse embryos were transduced in utero at 14 days
post coitum (dpc) with the PDGF-B/GFP expressing ret-
roviral vector described above. After birth, NG2-KO
injected animals were monitored daily for neurological
symptoms (e.g. lethargy, ataxia, imbalanced stance and
gait) which appeared in 90% of the animals (19 out of
21) within 280 days (Figure 2A). When explanted and
observed under fluorescence microscope, the brains of
all mice displaying symptoms showed wide masses of
GFP-positive cells as observed in PDGF-B transduced
wild type animals (Figure 2B-C). The survival of NG2-
KO mice (n = 21) was compared to that of a group of
wild type mice (n = 18) by applying the Log-rank test
which showed that there is no difference (p = 0.09) in
the survival of the two groups (Figure 2A). These data
indicate that PDGF-B-driven gliomagenesis occurs nor-
mally in the absence of NG2.
Moreover, similarly to PDGF-B-induced tumors in
wild type mice, NG2-KO gliomas showed all the typical
features of high grade human gliomas, such as densely
cellularized areas, highly vascularized regions and cells
with a remarkable ability to infiltrate the healthy areas
of the brain (Figure 2D-M). In particular, a quantitative
analysis showed that there were no differences in the
portion of tumor area occupied by blood vessels in
NG2-KO (3.2 ± 0.1%) and wild type (3.3 ± 0.7%; p =
0.9) mice (Additional file 1). Furthermore, neither NG2-
KO nor wild type showed any significant difference
in the density of infiltrating cells: (454 ± 24 cells/mm
2,
n = 727 and 382 ± 86 cells/mm
2,n =5 6 7 ,r e s p e c t i v e l y ;
p = 0.57).
However, it is important to note that PDGF-B
induced gliomagenesis could occur in NG2-KO mice
due to a compensatory event based on a higher activa-
tion of PDGFR-alpha or to a higher PDGF-B expres-
sion level. To rule out these possibilities we decided to
quantify the level of phosphorylated PDGFR-alpha pro-
tein and of PDGF-B mRNA. As shown in Additional
file 2A, despite some variability between tumors, a
similar fraction of PDGFR-alpha protein was activated
in wild type and NG2-KO tumor cells. Moreover, the
expression level of transduced PDGF-B did not show
any significant difference between the two animal
groups (p = 0.8; Additional file 2B). From all these
data we conclude that NG2 is not necessary for the
formation of gliomas induced by PDGF-B overexpres-
sion, in agreement with previous data obtained in
smooth muscle cells showing that PDGF-B signaling is
not altered in NG2-KO mice [13].
However, the above observations do not clarify
whether NG2 has a role in the determination of the
glioma subtype. We therefore analyzed tumors induced
by PDGF-B in NG2-KO mice by assessing the expres-
sion of a panel of markers which allow distinguishing
between different neural cell types. Analogously to
tumors induced in wild-type mice, those induced in
NG2-KOs did not express the astrocytic marker GFAP,
even if GFAP-positive reactive astrocytes were fre-
quently abundant within tumor masses (Figure 3A,B).
On the contrary, PDGF-B-induced gliomas expressed
high levels of oligodendrocyte progenitor markers such
as the transcription factor Olig2 and the receptor
P D G F R - a l p h a( F i g u r e3 C - F ) .T h eo n l yd i f f e r e n c ew e
found between tumor cells in NG2-KO and wild-type
mice was, obviously, the expression of NG2 (Figure 3G,
H), confirming the efficiency of the knockout. We there-
fore conclude that the lack of NG2 expression does not
affect the ability of PDGF-B overexpression to induce
tumors with oligodendroglial characteristics.
In primary PDGF-B-induced gliomas generated in wild
type animals, there are abundant untransduced (GFP-
negative) OPCs [23,24,36]. These cells are recruited to
the tumor mass by paracrine effects of PDGF and/or
other glioma-secreted factors and likely contribute to
the tumors high growth rate. We therefore evaluated
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mary NG2-KO tumors. Similarly to wild type PDGF-B-
induced tumors, NG2-KO gliomas harbored an abundant
population of recruited OPCs, as revealed by the expres-
sion of Olig2 and PDGFR-alpha by the GFP-negative
cells in the tumor infiltrated brain regions (Figure 4).
These findings suggest that resident OPC recruitment
occurs normally in NG2-KO gliomas, showing that NG2
is not necessary for the paracrine recruitment of resident
OPCs by PDGF-B-induced gliomas.
Figure 1 PDGF-B transduction induces an oligodendroglial fate in cultured neural progenitor cells. (A-B, left side) Histograms showing the
percentage of Olig2-positive cells in PDGF-B (red bars) and control (green bars) transduced cortical (A) and GE (B) cultures obtained from wild type
and NG2-KO embryos. (A-B, right side) Immunofluorescence micrographs of cortical (A) and GE (B) cultures derived from wild type and NG2-KO
mice following the transduction with PDGF-B/GFP or control retroviruses. The immunoreactivity to Olig2 and GFP is shown in red and in green,
respectively. NG2-KO cultures: nExp = 3; Wild type cultures: nExp = 2. *p < 0.05 and **p < 0.01 in a 2-tailed Student’s t-test. Scale bar: 50 μm.
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expression in NG2-KO mice maintain the ability to pro-
pagate as tumors after in vivo transplantation, as is
typical of those from wild type mice [25]. To this end,
we transplanted PDGF-B expressing glioma cells from
3 independent NG2-KO tumors into adult mouse
brains. Recipient mice were of either wild-type or
NG2-KO genotype. As shown in Figure 5A-B, 11 out
of 12 recipients developed secondary tumors within 85
days after transplantation. This frequency was com-
pared, with the Log-rank test, to the tumor occurrence
observed when wild type PDGF-B-induced glioma cells
were injected in wild type recipients (9 mice out of 12;
p > 0.05), revealing that NG2-KO glioma cells are able
to give rise to secondary tumors with high frequency,
indistinguishably from wild type tumors. In the above
Figure 2 PDGF-B overexpression induced gliomas in NG2-KO mice. (A) Survival curves following PDGF-B embryonic transduction of NG2-KO
(green line) and wild type (black line) mice. The Log-rank test performed on the survival curves of NG2-KO and wild type animals showed that
there are no significant differences (Log-rank Test = N.S.) between the two distributions. (B-C) Fluorescence images of PDGF-B-induced tumors in
NG2-KO (B) and wild type (C) mice. (D-M) Coronal sections of tumors obtained in NG2-KO (D, F, F’, H, I) or wild type (E, G, G’, L, M) mice stained
with DAPI for nuclear staining in blue and antibodies for the indicated antigens (D-G’, I, M) or with hematoxylin and eosin (H, L). F’ and G’ are
magnifications of the insets in figures F and G respectively, arrowheads point infiltrating cells. NT: non-tumor zone; T: highly cellularized tumor
zone. Scale bars: 0.5 mm (B-E); 100 μm (F-M).
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NG2-KO recipients were pooled, since no significant
difference was observed between the two groups (Addi-
tional file 3).
The histological analysis of the secondary tumors
derived from NG2-KO primary gliomas revealed large,
highly cellularized, compact masses with pseudopalisades
surrounding necrotic areas (Figure 5C-D). These obser-
vations demonstrate that secondary tumors from
NG2-KO mice are indistinguishable from those obtained
in wild type mice (Figure 5E-F) and possess a high
tumorigenic potential.
Figure 3 PDGF-B overexpression induced oligodendrogliomas in NG2-KO mice. (A-H) Immunofluorescence stainings of NG2-KO (A, C, E, G)
and wild type (B, D, F, H) glioma sections with anti-GFP antibody in green, DAPI for nuclear staining in blue and antibodies for the indicated
antigens in red. Scale bar: 50 μm.
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capability to be cultured in vitro maintaining the pheno-
typic and tumorigenic characteristics of the original
tumor [23,25]. We therefore tested this ability on 3
independent NG2-KO PDGF-B-induced tumors, and
observed that 2 of them could be maintained in vitro.
The immunocytochemical analysis showed that these
cells, similarly to their wild type counterparts expressed
Nestin, a marker for neural progenitor cells, the
OPC markers Olig2 and PDGFR-alpha, whereas they
were immuno-negative to the astrocytic marker GFAP
(Figure 6A-I).
Figure 4 PDGF-B-induced tumors recruit OPCs also in the absence of NG2 expression. (A-H) Immunofluorescence stainings of NG2-KO
(A-D) and wild type (E-H) glioma sections with anti-GFP antibody in green, DAPI for nuclear staining in blue and antibodies for the indicated
antigens in red. The left column of the figure corresponds to tumor infiltrated regions, while pictures on the right represent normal brain
regions next to tumor areas showing the basal level of OPC markers expression for comparison. Scale bars: 50 μm.
Terrile et al. BMC Cancer 2010, 10:550
http://www.biomedcentral.com/1471-2407/10/550
Page 8 of 14Figure 5 Cells derived from PDGF-B-induced gliomas are tumorigenic also in the absence of NG2 expression. (A) Survival curves
following transplantation into adult brains of PDGF-B-induced tumor cells derived from wild type (black line) or NG2-KO (green line) mice. The
Log-rank test performed on the two survival distributions showed that there are no significant differences (Log-rank Test = N.S.). (B) Fluorescence
image of a NG2-KO secondary tumor. (C-F) Coronal sections of secondary tumors derived from NG2-KO (C-D) or wild type (E-F) mice stained
with DAPI (C, E) or hematoxylin and eosin (D, F). NT: non-tumor zone; T: highly cellularized tumor zone; Dashed contours highlight the tumor
mass; arrows point pseudopalisade structures. Scale bars: 1 mm (B); 100 μm (C-F).
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malignant PDGF-B-induced gliomas is their in vitro
ability to override cell-cell contact-mediated inhibition
of proliferation [25]. We therefore evaluated the sensi-
tivity of NG2-KO glioma cells to increased cell density
in culture, and we observed that, like wild type cells,
NG2-KO tumor cells bypassed cell-cell contact inhibi-
tion and maintained their proliferative activity, even-
tually forming three dimensional cell foci (Figure 6L-M).
Moreover, a quantitative analysis performed by counting
the density of foci showed that there are no significant
differences in the ability to form foci between NG2-KO
and wild type glioma cells (see Additional file 4 as
example of the data obtained from this experiment).
Altogether these data clearly show that NG2 is not
necessary to maintain the phenotypic characteristics of
cultured PDGF-B-induced gliomas.
However, all the above observations do not exclude
the possibility that compensatory effects, which may
occur in NG2-KO embryos, could mask the actual role
of NG2 during the development of a glioma in a normal
c o n t e x t .W et h e r e f o r ea n a l y z e dt h i si s s u eb yu s i n ga n
engineered microRNA (miRNA-NG2) to silence NG2
expression in wild type PDGF-B induced glioma cells.
To test the silencing efficiency of the miRNA-NG2, we
transduced glioma cells, already expressing a PDGF-B/
DS Red vector, with retroviral vectors expressing GFP
and either the miRNA-NG2 or a negative control
miRNA (miRneg, not complementary to any cellular
mRNA) and, after 7 days, we compared the expression
Figure 6 PDGF-B-induced tumors can be propagated in culture also in the absence of NG2 expression .(A-H) Immunofluorescence
stainings of NG2-KO (A-D) and wild type (E-H) glioma cultures with anti-GFP antibody in green, DAPI for nuclear staining in blue and the
antibody for the indicated antigen in red. (I) Histogram showing the percentage of cells expressing the indicated markers in NG2-KO (red bars)
and wild type (blue bars) glioma cell cultures. (L-M) Bright field microphotographs of NG2-KO (L) and wild type (M) glioma cells showing the
ability to form foci in vitro. Scale bars: 50 μm (A-D); 100 μm (L-M).
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Page 10 of 14Figure 7 NG2 silencing does not impair the tumorigenic potential of cells derived from PDGF-B-induced tumors.( A - B )
Immunofluorescence stainings of PDGF-B-induced glioma cultures transduced with miR-NG2 (A) or miRneg (B) and stained with anti-GFP
antibody in green, anti-NG2 antibody in red and DAPI (nuclei) in blue. (C-D) Histograms showing the efficiency of miR-NG2 silencing in PDGF-B-
induced glioma cultures (C) or in cells extracted from a secondary tumor generated by the intracranial injection of PDGF-B-induced glioma cells
previously transduced with miR-NG2 (miR-NG2 secondary tumor; D). GFP positive cells represent glioma cells which were actually transduced
with miR-NG2, while GFP-negative cells were not transduced. (E) Fluorescence image of a miR-NG2 secondary tumor. (F) Immunofluorescence
staining of miR-NG2 secondary tumor cells with anti-GFP antibody in green, anti-NG2 antibody in red and DAPI (nuclei) in blue. Scale bars: 50
μm (A-B, F); 0.5 mm (E).
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Page 11 of 14of NG2 in the two conditions. As shown in Figure 7A-C,
the transduction of the miRNA-NG2 significantly
reduced NG2 expression from 88 ± 7% (n = 671) of con-
trol cells, to 32 ± 2% (n = 865, nExp = 2, ttest p < 0.05).
To evaluate the possibility that NG2 may be necessary
for the tumor-propagating potential of PDGF-B induced
gliomas, we transduced cells from two independent glio-
mas with the miRNA-NG2, the miRneg or a vector carry-
ing only GFP and we injected them into the brains of
adult mice (miRNA-NG2: n = 6; miRneg: n = 9 ; control
GFP: n = 18). Since the retroviral infections never
resulted in the transduction of all cells, we injected
mixed populations of transduced and untransduced cells.
We reasoned that if NG2 silencing exerted negative
effects on the tumorigenic potential of these cells, this
would result in the formation of GFP-depleted secondary
tumors. The use of mixed populations allowed us to have
an internal control of gliomagenesis that eliminated the
doubt about any technical problem which may occur
during injection. Moreover, to avoid stochastic cell popu-
lation effects from depleting secondary tumors of the
GFP-positive cell fractions, we only injected glioma
populations containing at least 40% GFP-positive cells.
After injection, no significant difference in the percentage
of GFP-positive secondary tumors was shown between
mice injected with miRNA-NG2- (67%) and control-
(67%) transduced cells (Table 1).
Since not all the cells expressing an engineered
miRNA usually reach an adequate level of gene silen-
cing, we quantified the percentage of NG2 expressing
cells in one miRNA-NG2 infected secondary glioma to
rule out the possibility that GFP-positive secondary
tumors would exclusively derive from cells maintaining
NG2 expression. As shown in Figure 7D-F, the level of
NG2 silencing in the secondary glioma cells is analogous
to that previously shown in vitro (Figure 7C). The per-
centage of cells expressing NG2 decreased from 88 ±
2% of GFP-negative cells (n = 176) to 36 ± 2% of GFP-
positive cells (n = 235).
All those data demonstrate that PDGF-B induced glio-
magenesis can occur after the abrogation of NG2
expression, thus raising serious doubts on the efficacy of
NG2 targeting as therapy against gliomas.
Discussion
The observation that human gliomas often highly
express NG2 suggested that this molecule could play an
important role in gliomagenesis [2,5,33,37]. This view is
corroborated by some preliminary data [33] and by the
observation that NG2 expression is important for some
OPCs to correctly proliferate during development [32]
and to respond to PDGF signaling [13,15]. Here, how-
ever, we showed that NG2 expression is not necessary
for the induction of OPC lineage features mediated by
PDGF-B overexpression, thus questioning the role of
NG2 for oligodendrocyte lineage determination.
Moreover, we tested the relevance of NG2 during
PDGF-B-induced gliomagenesis. Our results clearly show
that NG2 is dispensable for the formation of gliomas fol-
lowing the overexpression of PDGF-B and that tumors
induced in NG2-KO animals are indistinguishable from
those observed in wild type mice. This suggests that
tumor development occurred analogously in the two con-
texts. The similarities between NG2-KO and wild type
gliomas include the presence of highly infiltrating cells, a
typical feature of human gliomas, and vascularized areas
which ultimately require the induction of angiogenesis,
indicating that in this context this process is not signifi-
cantly influenced by the lack of NG2. Importantly, the
absence of NG2 did not significantly affect the ability of
gliomas to be maintained for long term in culture, to
override cell-cell contact inhibition of proliferation form-
ing cell foci in vitro and to regenerate a glioma after
orthotopic transplantation, all features representing func-
tional proxies for high malignancy [25].
Moreover, the use of an engineered miRNA directed
against NG2 in wild type glioma cells strengthens our
results, eliminating the possibility that glioma formation
in NG2-KO mice could be due to compensatory events
taking place in these animals. Our data also confirm
previous observations performed in different experimen-
tal systems [13] showing that NG2 is not able to bind
PDGF-B to influence PDGF-B-driven signaling, while
they reduce the expectations on the NG2 proteoglycan
as a target molecule useful to efficiently treat gliomas.
While our data show that NG2 is dispensable for
PDGF-B induced gliomagenesis, other authors reported
preliminary data from a somehow different system
(PDGF-B transduction in the adult white matter), point-
ing instead to a role for NG2 in this same process [33].
Lower transformation efficiencies (only 4 out of 11 wild
type mice developed a glioma), and as yet small experi-
mental numbers, may have contributed to this discre-
pancy, and a full report will be necessary for further
hypotheses to be drawn.
Table 1 NG2 silencing did not prevent tumorigenesis
driven by PDGF-B induced glioma cells
miR-NG2 control
GFP-positive tumors 66.7% 66.7%
GFP-negative tumors 16.7% 14.8%
not analyzed * 0% 7.4%
no tumor ** 16.7% 11.1%
The percentage of tumors for the indicated classes were shown. * Tumors
were not analyzed because the mice were found already dead and the
fluorescent signal was no more reliable due to autofluorescence. ** Mice that
did not develop a tumor.
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influence specifically PDGF-A-driven signaling and
PDGF-A can also induce the formation of gliomas
in vivo [22], NG2 could have a therapeutic role in
PDGF-A overexpressing gliomas. Moreover, since NG2
is highly expressed in human gliomas, it may be possible
to use it as a tag allowing the delivery of therapeutic
molecules to glioma cells.
Conclusions
We conclude that, unexpectedly, the lack of NG2 does not
prevent the generation of malignant gliomas driven by
PDGF-B overexpression. Moreover, an accurate compari-
son of gliomas induced by PDGF-B in NG2-KO and wild
type mice did not reveal any significant difference in terms
of tumor development, histopathology, molecular marker
expression, ability to propagate in vitro and to regenerate
tumors after orthotopic in vivo transplantation.
Questioning the potential role of NG2 in glioma for-
mation, our data reduce the expectations on the proteo-
glycan NG2 as a target molecule for the treatment of
this kind of tumor. We therefore think that our findings
are important to redirect the scientific research involved
in the development of new glioma therapies.
Additional material
Additional file 1: Lack of NG2 expression does not impair vessels
formation in PDGF-B-induced tumors. Histogram shows the
percentage of tumor area occupied by vessels (identified by immuno-
positivity to CD31 marker) in wild type and NG2-KO PDGF-B-induced
gliomas.
Additional file 2: The level of PDGFR-alpha activation and of PDGF-
B expression is similar in wild type and NG2-KO glioma cells.( A )
Western blot of two wild-type (WT) and two NG2-KO (KO) PDGF-B-
induced glioma cultures for the indicated proteins. The ratio between
the level of activated PDGFR-alpha and total PDGFR-alpha is shown in
the histogram. Values were normalized to the WT-1 culture. (B)
Histogram shows the levels of PDGF-B mRNA relative to the
housekeeping gene Rpl41 in wild type and NG2-KO glioma cultures.
Values represent the means of real-time PCR quantifications for two
independent cultures per condition.
Additional file 3: Cells derived from PDGF-B-induced gliomas
generated in NG2-KO mice are tumorigenic. Survival curves following
injection of PDGF-B induced tumor cells derived from NG2-KO mice into
NG2-KO (blue line) or wild type (red line) recipients.
Additional file 4: Cells derived from PDGF-B-induced tumors form
foci in vitro also in the absence of NG2 expression. Histogram shows
the average number of foci in the analyzed area (4 mm
2) for the wild
type and the NG2-KO glioma cultures (p = 0.7).
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